254 related articles for article (PubMed ID: 15831812)
1. Apolipoprotein A-I mimetic peptides.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Yu N; Ansell BJ; Datta G; Garber DW; Fogelman AM
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1325-31. PubMed ID: 15831812
[TBL] [Abstract][Full Text] [Related]
2. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
[TBL] [Abstract][Full Text] [Related]
3. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Hough G; Wagner A; Nakamura K; Garber DW; Datta G; Segrest JP; Hama S; Fogelman AM
Curr Opin Investig Drugs; 2003 Sep; 4(9):1100-4. PubMed ID: 14582455
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
Sherman CB; Peterson SJ; Frishman WH
Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
[TBL] [Abstract][Full Text] [Related]
5. Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action.
Getz GS; Wool GD; Reardon CA
Curr Opin Lipidol; 2009 Jun; 20(3):171-5. PubMed ID: 19373084
[TBL] [Abstract][Full Text] [Related]
6. Novel potent apoA-I peptide mimetics that stimulate cholesterol efflux and pre-beta particle formation in vitro.
Ingenito R; Burton C; Langella A; Chen X; Zytko K; Pessi A; Wang J; Bianchi E
Bioorg Med Chem Lett; 2010 Jan; 20(1):236-9. PubMed ID: 19932961
[TBL] [Abstract][Full Text] [Related]
7. ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose.
Carballo-Jane E; Chen Z; O'Neill E; Wang J; Burton C; Chang CH; Chen X; Eveland S; Frantz-Wattley B; Gagen K; Hubbard B; Ichetovkin M; Luell S; Meurer R; Song X; Strack A; Langella A; Cianetti S; Rech F; Capitò E; Bufali S; Veneziano M; Verdirame M; Bonelli F; Monteagudo E; Pessi A; Ingenito R; Bianchi E
Bioorg Med Chem; 2010 Dec; 18(24):8669-78. PubMed ID: 21115285
[TBL] [Abstract][Full Text] [Related]
8. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
Curr Opin Lipidol; 2004 Dec; 15(6):645-9. PubMed ID: 15529023
[TBL] [Abstract][Full Text] [Related]
9. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Wagner AC; Hama S; Hough G; Bachini E; Garber DW; Mishra VK; Palgunachari MN; Fogelman AM
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1932-7. PubMed ID: 15961700
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties.
Wool GD; Reardon CA; Getz GS
J Lipid Res; 2008 Jun; 49(6):1268-83. PubMed ID: 18323574
[TBL] [Abstract][Full Text] [Related]
11. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice.
Navab M; Hama S; Hough G; Fogelman AM
Circulation; 2003 Oct; 108(14):1735-9. PubMed ID: 14504179
[TBL] [Abstract][Full Text] [Related]
12. Point mutations in apolipoprotein A-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency.
Chroni A; Duka A; Kan HY; Liu T; Zannis VI
Biochemistry; 2005 Nov; 44(43):14353-66. PubMed ID: 16245952
[TBL] [Abstract][Full Text] [Related]
13. Potential clinical utility of high-density lipoprotein-mimetic peptides.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
Curr Opin Lipidol; 2006 Aug; 17(4):440-4. PubMed ID: 16832169
[TBL] [Abstract][Full Text] [Related]
14. Oral amphipathic peptides as therapeutic agents.
Reddy ST; Anantharamaiah GM; Navab M; Hama S; Hough G; Grijalva V; Garber DW; Datta G; Fogelman AM
Expert Opin Investig Drugs; 2006 Jan; 15(1):13-21. PubMed ID: 16370930
[TBL] [Abstract][Full Text] [Related]
15. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes.
Van Lenten BJ; Wagner AC; Navab M; Anantharamaiah GM; Hui EK; Nayak DP; Fogelman AM
Circulation; 2004 Nov; 110(20):3252-8. PubMed ID: 15533864
[TBL] [Abstract][Full Text] [Related]
16. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
Moradi H; Pahl MV; Elahimehr R; Vaziri ND
Transl Res; 2009 Feb; 153(2):77-85. PubMed ID: 19138652
[TBL] [Abstract][Full Text] [Related]
17. An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide.
Wool GD; Vaisar T; Reardon CA; Getz GS
J Lipid Res; 2009 Sep; 50(9):1889-900. PubMed ID: 19433476
[TBL] [Abstract][Full Text] [Related]
18. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol.
Mendez AJ; Anantharamaiah GM; Segrest JP; Oram JF
J Clin Invest; 1994 Oct; 94(4):1698-705. PubMed ID: 7929849
[TBL] [Abstract][Full Text] [Related]
19. Relevance of the amino acid conversions L144R (Zaragoza) and L159P (Zavalla) in the apolipoprotein A-I binding site for haptoglobin.
Cigliano L; D'Andrea LD; Maresca B; Serino M; Carlucci A; Salvatore A; Spagnuolo MS; Scigliuolo G; Pedone C; Abrescia P
Biol Chem; 2008 Nov; 389(11):1421-6. PubMed ID: 18783334
[TBL] [Abstract][Full Text] [Related]
20. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
